Analyst Price Target is $21.00
▲ +230.19% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Verona Pharma in the last 3 months. The average price target is $21.00, with a high forecast of $25.00 and a low forecast of $17.00. The average price target represents a 230.19% upside from the last price of $6.36.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Verona Pharma. This Buy consensus rating has held steady for over two years.
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.